Clinical Trials
2 trialsNCT00903968 2020-06-02
Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT01319864 2018-09-07
POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients
Seattle Children's Hospital
Phase 1 Completed